Intra-Cellular Therapies, Inc. reiterated earnings guidance for the full year 2024. Full year 2024, the company reiterated CAPLYTA net product sales guidance of $645 to $675 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.64 USD | -1.35% | -0.71% | -7.99% |
16/05 | Transcript : Intra-Cellular Therapies, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM | |
07/05 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.99% | 702.5Cr | |
-2.91% | 8.9TCr | |
-4.34% | 3.78TCr | |
-15.62% | 3.12TCr | |
+60.33% | 2.61TCr | |
-22.80% | 1.43TCr | |
-8.78% | 1.28TCr | |
-11.39% | 1.16TCr | |
+4.04% | 870.27Cr | |
-17.54% | 745.49Cr |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024